We recently compiled a list of the 10 Best Dow Jones Dividend Stocks According to Wall Street Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks.

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by a long shot.

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter Dannenbaum,

Merck stock was mangled on Tuesday after the company posted a 2025 EPS guidance well below Wall Street’s estimates.

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations with Keytruda sales.

Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year. Shares of the New Jersey-based maker of oncology best-seller Keytruda fell over 10% mid-session despite the company posting beats on the top and bottom lines in the fourth quarter.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Key Takeaways Merck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of estimates.Revenue and adjusted earnings, however, managed to top expectations.Sales of a few Merck drugs were hit by lower international demand and lower pricing in the U.